Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: William J. Leiby who wrote (590)	3/19/1998 10:27:00 AM
From: Bexar	Read Replies (1) \| Respond to of 849

GOOD NEWS !!! Matritech and Curtin Matheson Scientific/Fisher HealthCare Sign Distribution Agreement for Bladder Cancer Test PR Newswire, Thursday, March 19, 1998 at 08:46 NEWTON, Mass., March 19 /PRNewswire/ -- Matritech, Inc. (NASDAQ:NMPS) and Curtin Matheson Scientific (CMS) / Fisher HealthCare, a division of Fisher Scientific International Inc., announced today that the two companies have signed an agreement for CMS to distribute the Matritech NMP22(R) Test Kit for the management of bladder cancer patients, in the United States. CMS/Fisher HealthCare is a leader in the distribution of diagnostic products to clinical laboratories. "Based on the impressive clinical results of the test, we have selected NMP22 as our sole product for the management of bladder cancer patients. We believe that this product has the potential to bring significant value to a large patient population," said Jack Daniels, Vice President of Marketing for CMS/Fisher HealthCare. "CMS/Fisher HealthCare maintains a strong position in providing diagnostic products to the laboratory community, and we see NMP22 as a key addition to our current product portfolio." "CMS/Fisher HealthCare is a major distributor of diagnostic products with a strong business in hospital and clinical laboratories nationwide and a 170- person sales force," said David L. Corbet, President of Matritech. "Expanding our U.S. distribution is a key piece of Matritech's overall strategy for promoting the NMP22 Test Kit. We are also focused on continuing to target key thought leaders in the field and securing partners for automated testing systems." Matritech, Inc. based in Newton, Massachusetts, is using its proprietary nuclear matrix protein (NMP) technology, discovered at the Massachusetts Institute of Technology (MIT) and licensed exclusively to Matritech, to develop and commercialize innovative serum-, cell- and urine-based NMP diagnostics that enable physicians to reliably detect and monitor the presence of bladder, colon, cervical, breast and prostate cancers. Fisher Scientific is the world leader in serving science, providing more than 245,000 products and services to research, healthcare, industrial, educational and government customers in 145 countries. Except for historical information contained herein, the matters discussed in this news release are forward-looking statements that are subject to risks and uncertainties. Potential risks and uncertainties include, without limitation, potential fluctuations in the Company's sales due to the timing of customer orders and other market conditions beyond the Company's control, and risks related to the Company's ability to: successfully develop, test, produce, and market its products; obtain necessary government approvals in a timely manner; attract and keep key employees; raise capital for future operations and growth; and successfully respond to technological changes in the marketplace. Additional information on potential factors which could affect the Company's financial results are included in the Company's public filings with the Securities and Exchange Commission. SOURCE Matritech, Inc. -0- 03/19/98 /CONTACT: Stephen D. Chubb, CEO, or David L. Corbet, President of Matritech, Inc., 617-928-0820 or Paul Descheneaux of Director of Marketing of CMS, 281-878-3569 or Derek Caldwell of Sunrise Financial Group, 212-421-1616 or Robert Gottlieb or Gretchen L.P. Schweitzer of Feinstein Kean Partners, 617-577-8110/ Companies or Securities discussed in this article: Symbol Name NASDAQ:NMPS Matritech Inc